Drug profile · INN
bamlanivimab
BAMLANIVIMAB AND ETESEVIMAB FOR COVID-19
bamlanivimab (BAMLANIVIMAB AND ETESEVIMAB FOR COVID-19) is a spike glycoprotein inhibitor.
EMA: withdrawn from rolling review
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — bamlanivimab
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
bamlanivimab (BAMLANIVIMAB AND ETESEVIMAB FOR COVID-19) is a spike glycoprotein inhibitor.
Key facts
INN bamlanivimab
Brand BAMLANIVIMAB AND ETESEVIMAB FOR COVID-19
Mechanism Spike glycoprotein inhibitor
Target Spike glycoprotein
Mechanism of action
Spike glycoprotein inhibitor
Primary target: Spike glycoprotein
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | withdrawn from rolling review | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is bamlanivimab?
bamlanivimab (BAMLANIVIMAB AND ETESEVIMAB FOR COVID-19) is a spike glycoprotein inhibitor.
What is the brand name for bamlanivimab?
BAMLANIVIMAB AND ETESEVIMAB FOR COVID-19 is a marketed brand name for bamlanivimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.